News Sentiment

CVKD sentiment intelligence

Cadrenal Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 64 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.89 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 57

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-19.7% over one week, -21.9% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Cadrenal Therapeutics (CVKD) outlines $8.84M Rule 506(b) warrant financing

Market Reaction

Price moving ahead of tone

60/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -19.7% Price reacting lower
Trend fit Trend inactive -21.9% over four weeks
Fair value -73.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 40
Negative 12

Relevance

Why the article matched

Direct first
Direct company coverage 57
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 13
Market source 8
GlobeNewswire 7
Investing.com 5
TradingView 5
Quiver Quantitative 3
MT Newswires 2
simplywall.st 2

Event Lens

What the news is about

Classified themes
Market update 40
Earnings 17
Deals and strategy 3
Balance sheet 2
Guidance 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 64
Investing.com Direct company coverage

Cadrenal’s HIT drug data selected for presentation at Paris congress

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced that clinical data for its drug candidate CAD-1005 has been accepted for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis. This presentation will cover results from a Phase 2 t

Tone
Positive 71/100
Event
Earnings
Published
24 Jun 2026 13:41
Source
Investing.com
Investing.com Australia Direct company coverage

Cadrenal’s HIT drug data selected for presentation at Paris congress By Investing.com

Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced that clinical data for its drug candidate CAD-1005 has been selected for an oral presentation at the 34th Congress of the International Society on Thrombosis and Haemostasis in Paris. The presentation will detail results from a

Tone
Positive 67/100
Event
Earnings
Published
24 Jun 2026 12:40
Source
Investing.com Australia
GlobeNewswire Direct company coverage

Cadrenal Therapeutics Announces Selection of CAD-1005 Phase

Cadrenal Therapeutics (Nasdaq: CVKD) announced that its Phase 2 study for CAD-1005, a 12-lipoxygenase inhibitor for Heparin-Induced Thrombocytopenia (HIT), has been selected for a late-breaking oral presentation at the ISTH 2026 Congress. This is the first randomized, blinded, pl

Tone
Positive 71/100
Event
Market update
Published
24 Jun 2026 11:40
Source
GlobeNewswire